

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6188319

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST

CONVEYING PARTY DATA

Name	Execution Date
SILICON VALLEY BANK	07/06/2020

RECEIVING PARTY DATA

Name:	CLEARSIDE BIOMEDICAL, INC.
Street Address:	900 NORTH POINT PARKWAY
Internal Address:	SUITE 200
City:	ALPHARETTA
State/Country:	GEORGIA
Postal Code:	30005

PROPERTY NUMBERS Total: 41

Property Type	Number
Application Number:	15619065
Patent Number:	10188550
Patent Number:	9539139
Patent Number:	9180047
Patent Number:	9636253
Patent Number:	9770361
Patent Number:	9937075
Patent Number:	9956114
Patent Number:	D750223
Application Number:	15427823
Application Number:	15675035
Patent Number:	9636332
Patent Number:	9572800
Patent Number:	9931330
Application Number:	15830727
Application Number:	11709941
Application Number:	15398538
Application Number:	15872206
Application Number:	15946838

PATENT

Property Type	Number
Application Number:	16381213
Application Number:	13273775
Application Number:	13842218
Application Number:	13842288
Application Number:	14424685
Application Number:	14441151
Application Number:	14821310
Application Number:	15454636
Application Number:	16318804
Application Number:	16178162
PCT Number:	US2017065796
Application Number:	16041067
Application Number:	16124407
Application Number:	15319045
Application Number:	62748788
PCT Number:	US2018062712
Application Number:	62638744
Application Number:	62793562
Application Number:	16292845
Application Number:	62769659
Application Number:	62830802
Application Number:	62834554

CORRESPONDENCE DATA

Fax Number: (202)842-7899

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 202-842-7800

Email: zIPPatentDocketingMailboxUS@cooley.com, schandy@cooley.com

Correspondent Name: COOLEY LLP - ATTN. PATENT GROUP

Address Line 1: 1299 PENNSYLVANIA AVE, NW

Address Line 2: SUITE 700

Address Line 4: WASHINGTON, D.C. 20004

ATTORNEY DOCKET NUMBER:	317302-2000
NAME OF SUBMITTER:	MEGHANN K. TEAGUE
SIGNATURE:	/Meghann K. Teague/
DATE SIGNED:	07/07/2020

Total Attachments: 5
source=Clearside-SVP IP Release of Security Interest#page1.tif

source=Clearside-SVP IP Release of Security Interest#page2.tif

source=Clearside-SVP IP Release of Security Interest#page3.tif

source=Clearside-SVP IP Release of Security Interest#page4.tif

source=Clearside-SVP IP Release of Security Interest#page5.tif

RELEASE OF SECURITY INTEREST

This Release of Security Interest ("**Release**") is executed as of July 6, 2020, by SILICON VALLEY BANK, a California Corporation, as collateral agent ("**Assignor**"), for the benefit of CLEARSIDE BIOMEDICAL, INC., a Delaware corporation ("**Assignee**").

RECITALS

WHEREAS, Assignee granted and pledged certain security interests in the intellectual property described on Exhibit A and Exhibit B attached hereto (collectively, the "**Intellectual Property**") to the Assignor pursuant to the Loan and Security Agreement, dated as of May 14, 2018 (as amended, restated, supplemented or otherwise modified from time to time, the "**Security Agreement**"), and recorded with the U.S. Patent and Trademark Office on August 29, 2019 at Reel/Frame 050217/0270 and Reel/Frame 6733/0277.

WHEREAS, Assignor wishes to release and reassign all interest that Assignor may have in the Intellectual Property as granted pursuant to the Security Agreement.

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor hereby states as follows:

1. Release of Security Interest. Assignor and its successors, legal representatives and assigns, hereby totally and permanently terminates, releases and discharges any and all security interests that it has pursuant to the Security Agreement in

(a) any and all patents, patent applications and other patent rights and any other governmental authority-issued indicia of invention ownership, including the patents listed in Exhibit A hereto, and all reissues, divisions, continuations, continuations-in-part, renewals, extensions and reexaminations thereof and amendments thereto (the "**Patents**"); and

b) any and all trademarks, service marks, trade names, brand names, logos, trade dress, design rights and other similar designations of source, whether registered or unregistered, including the trademark registrations and applications set forth in Exhibit B hereto, together with the goodwill connected with the use thereof and symbolized thereby and all extensions and renewals thereof (the "**Trademarks**").

2. Disclaimer of Any Other Interest. Assignor and its successors, legal representatives and assigns, hereby totally and permanently terminates, releases and discharges all other right, title, and interest (if any) it may have in the Intellectual Property.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, Bank has caused this Release to be duly executed and delivered by its officer thereunto duly authorized as of the date first above written.

ASSIGNOR:

SILICON VALLEY BANK


DocuSigned by:

By: 081B8D5A8EDB415
Name: M Scott McCarty
Title: Director

EXHIBIT A

Patents

<u>Description</u>	<u>Registration/ Application Number</u>	<u>Registration/ Application Date</u>
Apparatus and methods for drug delivery using microneedles	15619065	6/9/17
Apparatus and methods for drug delivery using multiple reservoirs	10188550	1/29/19
Apparatus and methods for ocular injection	9539139	1/10/17
Apparatus and methods for ocular injection	9180047	11/10/15
Apparatus and methods for ocular injection	9636253	5/2/17
Apparatus and methods for ocular injection	9770361	9/26/17
Apparatus and methods for ocular injection	9937075	4/10/18
Variable diameter cannula and methods for controlling insertion depth for medicament delivery	9956114	5/1/18
Medical injector for ocular injection	D750223	2/23/16
Ocular injection kit, packaging, and methods of use	15427823	2/8/17
Devices and methods for adjusting the insertion depth of a needle for medicament delivery	15675035	8/11/17
Methods and devices for the treatment of ocular diseases in human subjects	9636332	5/2/17
Methods and devices for the treatment of ocular diseases in human subjects	9572800	2/21/17
Methods and devices for the treatment of ocular diseases in human subjects	9931330	4/3/18
Methods and devices for the treatment of ocular diseases in human subjects	15830727	12/4/17
Apparatus and formulations for suprachoroidal drug delivery	11709941	2/21/07
Apparatus and formulations for suprachoroidal drug delivery	15398538	1/4/17
Device for ocular access	15872206	1/16/18
Apparatus and methods for ocular injection	15946838	4/6/18
Apparatus and methods for ocular injection	16381213	4/11/19

Device for ocular access	13273775	10/14/11
Apparatus and formulations for suprachoroidal drug delivery	13842218	3/15/13
Apparatus and formulations for suprachoroidal drug delivery	13842288	3/15/13
Apparatus and methods for drug delivery using microneedles	14424685	2/27/15
Methods and devices for the treatment of ocular diseases in human subjects	14441151	5/6/15
Device for ocular access	14821310	8/7/15
Methods and devices for the treatment of ocular diseases in human subjects	15454636	3/9/17
Formulations for the Suprachoroidal Space of an Eye and Methods	16318804	1/18/19
Systems and Methods for Ocular Drug Delivery	16178162	5/2/17
Systems and Methods for Delivering Drugs to Retinal Tissue	PCT/US2017065796	12/12/17
Methods and Devices for the Treatment of Ocular Diseases in Human Subjects	16041067	7/20/18
Methods and Devices for the Treatment of Ocular Diseases in Human Subjects	16124407	9/7/18
Methods and Devices for Treating Posterior Ocular Disorders	15319045	6/17/15
Gene Therapy for Ocular Improvement	62748788	10/22/18
Gene Therapy for Ocular Improvement	PCT/US2018062712	11/28/18
Compositions and Methods for Treating Noninfectious Uveitis	62638744	3/5/18
Compositions and Methods for Treating Noninfectious Uveitis	62793562	1/17/19
Compositions and Methods for Treating Noninfectious Uveitis	16292845	3/5/19
Thalidomide Derivatives and Methods of Use Thereof in Ocular Disorders	62769659	11/20/18
Plasma Kallikrein Inhibitors and Methods of Use Thereof in Ocular Disorders	62830802	4/8/19
Injectable Triamcinolone Formulations	62834554	4/16/19

EXHIBIT B

Trademarks

<u>Description</u>	<u>Registration/ Application Number</u>	<u>Registration/ Application Date</u>
XIPERE	88221046	12/7/18
SCS MICROINJECTOR	87897002	4/27/18
XIPERE	87896124	4/27/18
SCS	86636301	5/20/15
CS	85639727	5/31/12
CLEARSIDE BIOMEDICAL	85561295	3/6/12
CS CLEARSIDE BIOMEDICAL	85561286	3/6/12